Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 4/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 6/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2712104 | 0.83 | KDM4E (0.49) | NT5EADORA2AADORA1KDM4EPOLB | |
| SCHEMBL23716945 | 0.81 | ADRB2 (0.55) | NT5EADORA2AADORA1KDM4ECDK8 | |
| SCHEMBL4214227 | 0.81 | NT5E (0.69) | NT5EADORA2AADORA1KDM4EPOLB | |
| SCHEMBL11828378 | 0.81 | NT5E (0.51) | NT5EADORA2AADORA1KDM4ECDK8 | |
| SCHEMBL1536339 | 0.81 | NT5E (0.70) | NT5EADORA2AADORA1KDM4ECDK8 | |
| SCHEMBL3823152 | 0.79 | NT5E (0.49) | NT5EKDM4EALDH1A1KMT2AMPO | |
| SCHEMBL28019418 | 0.79 | NT5E (0.56) | NT5EADORA2AADORA1KDM4EPOLB | |
| SCHEMBL11669211 | 0.79 | DHODH (0.56) | NT5ECDK8CLK2ACVR1CLK4 | |
| SCHEMBL2425907 | 0.79 | ADORA2A (0.58) | NT5EADORA2AADORA1POLBLMNA | |
| SCHEMBL2854016 | 0.78 | IGF1R (0.48) | NT5EADORA2AADORA1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| CN-114867719-A | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2022-08-05 | — | — | CN | disclosed |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORPORATION (KR) | 2021-05-20 | — | — | US | disclosed |
| US-9566284-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2017-02-14 | — | — | US | disclosed |
| US-9566284-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2017-02-14 | — | — | US | disclosed |
| US-9334256-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2016-05-10 | — | — | US | disclosed |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO INC. (CA) | 2014-08-21 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2011-10-13 | — | — | US | disclosed |
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2011-10-13 | — | — | US | disclosed |
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2009-08-27 | — | — | US | disclosed |
| US-7514432-B2 | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2009-04-07 | — | — | US | disclosed |
| US-20060183749-A1 | Novel compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2006-08-17 | — | — | US | disclosed |
| EP-1597253-B1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2006-08-09 | — | — | EP | disclosed |
| EP-1597253-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | Exonhit Therapeutics S.A. (FR) | 2005-11-23 | — | — | EP | disclosed |
| EP-1471063-A1 | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | Exonhit Therapeutics S.A. (FR) | 2004-10-27 | — | — | EP | disclosed |
| WO-2004076445-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | TRPM7, TRPM8, TRPM6 | NT5E 1414/4885ADORA2A 813/4885ADORA1 1919/4885 |
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | RB1, ALDH1A2, CDK4 | NT5E 3559/4885ADORA2A 2827/4885ADORA1 3461/4885 |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | TRPM7, TRPM8, TRPM6 | NT5E 1414/4885ADORA2A 813/4885ADORA1 1919/4885 |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | NT5E 957/4885ADORA2A 2766/4885ADORA1 3057/4885 |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | TRPM7, TRPM8, TRPM5 | NT5E 1138/4885ADORA2A 1069/4885ADORA1 1408/4885 |
| US-20060183749-A1 | Novel compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | RB1, ALDH1A2, CDK4 | NT5E 3559/4885ADORA2A 2827/4885ADORA1 3461/4885 |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | FAP, APC, VHL | NT5E 957/4885ADORA2A 2766/4885ADORA1 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.